Integrated Diagnostics Appoints Dr. Albert Luderer to Serve as CEO
29 March 2010
Senior Life Sciences Executive Will Lead Emerging Personalized Diagnostics Company Founded by Dr. Leroy Hood
SEATTLE — Integrated Diagnostics, a personalized diagnostics company founded by Dr. Leroy Hood, today announced that Dr. Albert Luderer has been appointed by the Board of Directors to serve as CEO. Dr. Luderer was previously president and CEO of BioTrove, a venture-backed molecular biological tools company that was acquired by Life Technologies in December 2009. He brings to Integrated Diagnostics an extensive track record of leadership in medical diagnostics, laboratory medicine and therapeutic development.
Integrated Diagnostics, which raised a $30 Million Series A in September 2009, is an emerging leader in developing personalized and preventive diagnostics. The company uses genomic and proteomic techniques to identify blood proteins that are only synthesized in the organ of interest and then identifies subtle changes that result from disease or treatment. By monitoring concentrations of these proteins in the blood, disruptions in healthy function can be detected and traced back to the diseased organ.
“With a unique technology platform and access to Lee Hood’s research into protein blood markers, Integrated Diagnostics is on the leading edge of diagnostics,” said Dr. Luderer. “The company has all the elements necessary for success: potentially game-changing science, novel technology platforms, a world-class scientific team and visionary investors. I am very excited to be working with this extraordinary group to develop novel diagnostic tools to help patients and physicians detect disease in its earliest stages.”
The company’s proprietary protein panels are applicable to many diagnostic modalities including early detection of disease, stratification of disease types, and monitoring disease progression and recurrence. The company’s technology is pertinent to a broad scope of diseases, including cancer, diabetes and Alzheimer’s disease. “Al’s proven record in diagnostic development and commercialization will be essential to Integrated Diagnostics as we advance our diagnostics platform and develop the next generation of tools for diagnosing and preventing disease,” said Dr. Leroy Hood, founder of Integrated Diagnostics and president of The Institute for Systems Biology (ISB). “Al’s experience as a successful scientist and entrepreneur will be critical to leading the company and advancing a health care environment that is predictive, preventive, personalized and participatory.”
Dr. Luderer brings more than 30 years of experience in biotechnology, with a focus on technology development, business development and commercialization. During his tenure at BioTrove the company was the 2009 recipient of Frost & Sullivan’s North American Drug Discovery Technologies and Growth Strategy Leadership of the Year Award and was recognized by Inc. magazine as one of the fastest growing companies in North America. Previously, Dr. Luderer was CEO of the venture-backed therapeutics company Light Sciences Inc and president and COO of bioMérieux, Inc. Earlier in his career he held senior management positions at Dianon Systems (now Lab Corp), Boehringer Mannheim (Now Roche) and Corning. Dr. Luderer has developed and commercialized major in vitro diagnostics (IVD) systems including Vitek® II – the global market leader for microbial detection and antibiotic susceptibility testing – and has co-invented and established standard of care diagnostics in cancer detection. He participated in the creation of one of the dominant IVD companies – Siemens Diagnostics – through his participation in the negotiation and formation of the joint venture IVD firm Ciba Corning. Dr. Luderer holds a PhD from Rutgers University where he was a National Science Foundation predoctoral fellow and performed postgraduate work in immunology at Jefferson Medical College. He is an independent director of Agendia BV and Micronics Inc. – and is an advisor to Washington University’s Biomedical Engineering program.
About Integrated Diagnostics
The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products and measurement technologies that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer’s through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company is developing a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.
In September 2009 Integrated Diagnostics raised a $30 million Series A round of financing led by InterWest Partners, a diversified venture capital firm, and joined by The Wellcome Trust and dievini Hopp Biotech holding. Dievini’s participation in the Series A financing is part of a collaboration with the Grand Duchy of Luxembourg. Integrated Diagnostics is the first commercial enterprise to emerge from a unique $200 million public-private partnership – announced in 2008 – between the nation of Luxembourg and three American research institutions, including ISB. As part of the investment, Integrated Diagnostics has access to research from the ongoing research collaboration in systems biology between the University of Luxembourg and ISB, which also involves the development of the Luxembourg Centre for Systems Biomedicine.